Roberto Mignone Sells 367,600 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Posted by Stanley Muller on Sep 22nd, 2026

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a filing with the SEC, which is available through this link.

Teva Pharmaceutical Industries Trading Down 1.3%

Shares of TEVA traded down $0.50 on Tuesday, reaching $39.56. 4,542,452 shares of the company’s stock were exchanged, compared to its average volume of 6,865,540. The business has a 50 day moving average price of $35.58 and a two-hundred day moving average price of $33.60. Teva Pharmaceutical Industries Ltd. has a 12 month low of $18.21 and a 12 month high of $40.79. The stock has a market capitalization of $46.10 billion, a P/E ratio of 65.93, a price-to-earnings-growth ratio of 4.86 and a beta of 0.87. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion for the quarter. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on TEVA. Barclays lifted their target price on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings cut shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.10.

Read Our Latest Stock Report on Teva Pharmaceutical Industries

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc boosted its position in shares of Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after acquiring an additional 228,189 shares during the period. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $1,098,060,000. Y Intercept Hong Kong Ltd acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth approximately $9,126,000. TD Asset Management Inc increased its stake in Teva Pharmaceutical Industries by 47.1% during the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock worth $11,517,000 after acquiring an additional 118,075 shares during the period. Finally, WCM Investment Management LLC increased its position in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.